Susquehanna International Group, LLP Jounce Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

16 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	SELL	$2.8 - $7.67 $75,600 - $207,090	-27,000 Reduced 50.19%	26,800 $81,000
Q1 2022 May 16, 2022	BUY	$6.01 - $8.54 $84,140 - $119,559	14,000 Added 35.18%	53,800 $365,000
Q4 2021 Feb 14, 2022	BUY	$7.11 - $9.64 $9,954 - $13,496	1,400 Added 3.65%	39,800 $332,000
Q3 2021 Nov 15, 2021	BUY	$5.04 - $8.73 $64,008 - $110,871	12,700 Added 49.42%	38,400 $285,000
Q2 2021 Aug 11, 2021	BUY	$6.58 - $10.66 $26,978 - $43,706	4,100 Added 18.98%	25,700 $175,000
Q1 2021 May 17, 2021	SELL	$6.73 - $13.87 $179,691 - $370,329	-26,700 Reduced 55.28%	21,600 $222,000
Q4 2020 Feb 16, 2021	SELL	$6.37 - $10.33 $274,547 - $445,223	-43,100 Reduced 47.16%	48,300 $338,000
Q3 2020 Nov 16, 2020	BUY	$4.58 - $10.95 $291,746 - $697,515	63,700 Added 229.96%	91,400 $746,000
Q2 2020 Aug 14, 2020	SELL	$4.17 - $7.58 $105,918 - $192,532	-25,400 Reduced 47.83%	27,700 $191,000
Q1 2020 May 15, 2020	BUY	$2.91 - $8.7 $53,253 - $159,210	18,300 Added 52.59%	53,100 $252,000
Q4 2019 Feb 14, 2020	BUY	$2.81 - $9.21 $67,440 - $221,040	24,000 Added 222.22%	34,800 $304,000
Q3 2019 Nov 14, 2019	SELL	$3.33 - $4.93 $38,295 - $56,695	-11,500 Reduced 51.57%	10,800 $36,000
Q2 2019 Aug 14, 2019	BUY	$4.3 - $6.73 $5,590 - $8,749	1,300 Added 6.19%	22,300 $110,000
Q3 2018 Nov 14, 2018	SELL	$6.5 - $8.37 $304,200 - $391,715	-46,800 Reduced 69.03%	21,000 $137,000
Q2 2018 Aug 14, 2018	SELL	$7.27 - $21.88 $985,812 - $2.97 Million	-135,600 Reduced 66.67%	67,800 $519,000
Q1 2018 May 15, 2018	BUY	$13.4 - $28.4 $2.73 Million - $5.78 Million	203,400 New	203,400 $4.55 Million

Others Institutions Holding JNCE

# of Institutions

Shares Held

720K

Call Options Held

Put Options Held

View Full List

About Jounce Therapeutics, Inc.

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

More about JNCE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account